Biotech

Leap Therapeutics (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising clinical data from the study evaluating DKN-01, Leap’s anti-DKK1 monoclonal antibody, as a monotherapy in patients with advanced esophagogastric cancer.  In addition, Leap announced that the first patient has been enrolled in the study evaluating DKN-01 in patients with gynecological cancers. …

Leap Therapeutics (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising clinical data from the study evaluating DKN-01, Leap’s anti-DKK1 monoclonal antibody, as a monotherapy in patients with advanced esophagogastric cancer. In addition, Leap announced that the first patient has been enrolled in the study evaluating DKN-01 in patients with gynecological cancers. Leap also announced two upcoming scientific presentations at the American Association for Cancer Research (AACR) 2018 Annual Meeting.

As quoted in the press release:

“The results of the DKN-01 monotherapy cohort demonstrate promising single agent activity in a very difficult to treat population of heterogeneous esophagogastric cancer. This data, in addition to the encouraging activity we have seen with DKN-01 in preclinical models and in patients in combination with chemotherapy, provides a strong foundation for our ongoing study in combination with the anti-PD-1 therapy Keytruda®,” commented Cynthia Sirard, MD, Vice President of Clinical Development for Leap.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX19984.53-636.86
TSXV807.51-49.11
DOW33334.87-930.50
S&P 5004249.51-148.43
NASD13199.29-569.63
ASX7175.80-166.60

COMMODITIES

Commodities
Gold1835.10+0.91
Silver23.65-0.62
Copper4.40-0.13
Palladium2148.50+51.50
Platinum1013.00-17.00
Oil82.23-2.91
Heating Oil2.57-0.07
Natural Gas4.01+0.01

DOWNLOAD FREE REPORTS

×